Target intelligence / Profile preview

EYA transcriptional coactivator and phosphatase 3 (EYA3)

Target
EYA3
Molecular classification
Enzyme (specifically phosphatase: protein tyrosine phosphatase and threonine phosphatase), Transcriptional coactivator, Other (unique dual-function, as both enzyme and coactivator)
01

Overview

EYA transcriptional coactivator and phosphatase 3 (EYA3) is a member of the Eyes absent (EYA) family, uniquely defined by dual functionality as a transcriptional coactivator and a protein phosphatase. Its C-terminal EYA domain confers tyrosine phosphatase activity, critical for dephosphorylating the 'Tyr-142' residue of histone H2AX, thereby promoting DNA repair and modulating apoptotic responses. Its N-terminal domain associates with the PP2A holoenzyme, imparting threonine phosphatase activity that regulates key cell cycle proteins such as c-Myc, stabilizing them and promoting cell proliferation, motility, and survival. EYA3 serves as a transcriptional coactivator, partnering with SIX1 and related proteins to regulate transcription and developmental processes. Aberrant EYA3 activity or expression is implicated in diverse pathologies, most notably metastatic cancers and developmental syndromes, making it a candidate therapeutic target under ongoing investigation.

Other names
Eyes absent homolog 3Eyes absent protein 3
02

Mechanism of action

Inhibitors would block phosphatase activity (tyrosine and threonine) and transcriptional coactivation, affecting cell proliferation, survival, and DNA repair, thereby reducing tumor growth/metastasis. Mechanism is context-dependent; modulation of PP2A interaction disrupts threonine phosphatase function.

03

Biological functions

DNA repair (via H2AX dephosphorylation)Transcriptional regulationCell survival and chemoresistanceCell proliferationCell motilityDevelopmental processes (organogenesis, tissue homeostasis)Apoptosis (indirect through H2AX signaling)
04

Disease associations

Cancer (including breast cancer, sarcoma, Ewing sarcoma; oncogenic and metastatic roles)Deafness, Autosomal Dominant 10Developmental disorders (syndromic/non-syndromic)
05

Safety considerations

Targeting EYA3 may affect normal tissue development and homeostasis, potentially leading to off-target effects (due to its role in organogenesis and DNA repair)Potential risk for immune and developmental dysfunction if broadly inhibited
06

Biomarkers

Upregulated EYA3 mRNA/protein for poor prognosis in certain cancers (experimental/preclinical context; notably Ewing sarcoma, breast cancer)EYA3 activity may correlate with c-Myc stabilization and DNA repair capacity

Beyond the preview

Go deeper on EYA transcriptional coactivator and phosphatase 3 (EYA3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on EYA transcriptional coactivator and phosphatase 3 (EYA3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call